$FATE
Fate Therapeutics Inc

2023 Q3 Form 10-Q Financial Statement

#000095017023039803 Filed on August 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $1.944M $933.0K
YoY Change -87.02% -94.97%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $18.95M $22.62M
YoY Change -12.09% 11.16%
% of Gross Profit
Research & Development $34.28M $40.88M
YoY Change -57.06% -49.73%
% of Gross Profit
Depreciation & Amortization $4.740M $4.466M
YoY Change 48.45% 50.78%
% of Gross Profit
Operating Expenses $53.22M $63.50M
YoY Change -47.5% -37.54%
Operating Profit -$51.28M -$62.57M
YoY Change -40.64% -24.72%
Interest Expense $5.750M $4.774M
YoY Change 114.71% -28.08%
% of Operating Profit
Other Income/Expense, Net $6.109M $5.036M
YoY Change 116.02% -28.1%
Pretax Income -$45.17M -$52.76M
YoY Change -45.94% -30.68%
Income Tax
% Of Pretax Income
Net Earnings -$45.17M -$52.76M
YoY Change -45.94% -30.68%
Net Earnings / Revenue -2323.56% -5654.34%
Basic Earnings Per Share -$0.46 -$0.54
Diluted Earnings Per Share -$0.46 -$0.54
COMMON SHARES
Basic Shares Outstanding 98.56M 98.38M
Diluted Shares Outstanding 98.57M 98.40M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $349.7M $377.9M
YoY Change -30.77% -33.56%
Cash & Equivalents $33.33M $46.80M
Short-Term Investments $316.4M $331.1M
Other Short-Term Assets $12.90M $11.41M
YoY Change -35.4% -33.57%
Inventory
Prepaid Expenses
Receivables $1.538M $2.833M
Other Receivables $0.00 $0.00
Total Short-Term Assets $364.2M $392.2M
YoY Change -31.97% -34.54%
LONG-TERM ASSETS
Property, Plant & Equipment $101.7M $170.1M
YoY Change -6.79% 64.93%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $7.291M
YoY Change -100.0% -38.86%
Other Assets $9.000K $15.21M
YoY Change -72.73% 45990.91%
Total Long-Term Assets $179.6M $192.6M
YoY Change -16.08% -7.37%
TOTAL ASSETS
Total Short-Term Assets $364.2M $392.2M
Total Long-Term Assets $179.6M $192.6M
Total Assets $543.8M $584.8M
YoY Change -27.43% -27.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.706M $7.506M
YoY Change -40.52% -10.86%
Accrued Expenses $28.54M $35.26M
YoY Change -43.09% -13.0%
Deferred Revenue $1.110M $1.929M
YoY Change -96.85% -94.27%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $41.33M $44.69M
YoY Change -60.23% -51.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $99.70M $102.3M
YoY Change -21.75% -24.25%
Total Long-Term Liabilities $99.70M $102.3M
YoY Change -21.75% -24.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $41.33M $44.69M
Total Long-Term Liabilities $99.70M $102.3M
Total Liabilities $141.0M $147.0M
YoY Change -39.05% -35.12%
SHAREHOLDERS EQUITY
Retained Earnings -$1.168B -$1.122B
YoY Change 17.41% 23.23%
Common Stock $99.00K $99.00K
YoY Change 2.06% 2.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $402.8M $437.8M
YoY Change
Total Liabilities & Shareholders Equity $543.8M $584.8M
YoY Change -27.43% -27.54%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$45.17M -$52.76M
YoY Change -45.94% -30.68%
Depreciation, Depletion And Amortization $4.740M $4.466M
YoY Change 48.45% 50.78%
Cash From Operating Activities -$38.28M -$28.49M
YoY Change -30.46% -46.4%
INVESTING ACTIVITIES
Capital Expenditures $560.0K $2.199M
YoY Change -106.45% -121.71%
Acquisitions
YoY Change
Other Investing Activities $25.37M $35.37M
YoY Change -71.51% -29.85%
Cash From Investing Activities $24.80M $33.17M
YoY Change -69.15% -17.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 58.00K
YoY Change -100.0% -98.3%
NET CHANGE
Cash From Operating Activities -38.28M -28.49M
Cash From Investing Activities 24.80M 33.17M
Cash From Financing Activities 0.000 58.00K
Net Change In Cash -13.48M 4.732M
YoY Change -150.26% -149.99%
FREE CASH FLOW
Cash From Operating Activities -$38.28M -$28.49M
Capital Expenditures $560.0K $2.199M
Free Cash Flow -$38.84M -$30.69M
YoY Change -16.24% -28.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
dei Entity Central Index Key
EntityCentralIndexKey
0001434316
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
CY2022Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
ecd Trd Arr Adoption Date
TrdArrAdoptionDate
April 5, 2023
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36076
dei Entity Registrant Name
EntityRegistrantName
FATE THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
65-1311552
dei Entity Address Address Line1
EntityAddressAddressLine1
12278 Scripps Summit Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92131
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
875-1800
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
FATE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
98562432
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46802000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61333000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2833000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
38480000
CY2023Q2 fate Short Term Investments And Related Maturity Receivables
ShortTermInvestmentsAndRelatedMaturityReceivables
331133000
CY2022Q4 fate Short Term Investments And Related Maturity Receivables
ShortTermInvestmentsAndRelatedMaturityReceivables
374894000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11414000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
27367000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
392182000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
502074000
CY2023Q2 us-gaap Long Term Investments
LongTermInvestments
7291000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
4942000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
106331000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
110020000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
63743000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
66069000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
15177000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
15227000
CY2023Q2 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
0
CY2022Q4 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
7196000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000
CY2023Q2 us-gaap Assets
Assets
584757000
CY2022Q4 us-gaap Assets
Assets
705561000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
7506000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8265000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
29469000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53932000
CY2023Q2 fate Cirm Award Liability Current
CIRMAwardLiabilityCurrent
0
CY2022Q4 fate Cirm Award Liability Current
CIRMAwardLiabilityCurrent
4000000
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1929000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
42226000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5786000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5628000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
44690000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
114051000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
100562000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
103710000
CY2023Q2 fate Stock Price Appreciation Milestones Liabilities Non Current
StockPriceAppreciationMilestonesLiabilitiesNonCurrent
1750000
CY2022Q4 fate Stock Price Appreciation Milestones Liabilities Non Current
StockPriceAppreciationMilestonesLiabilitiesNonCurrent
3861000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
3000
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
3000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
98522718
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
98522718
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
97294917
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
97294917
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
99000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
97000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1560680000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1536497000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-587000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1854000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1122440000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1050804000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
437755000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
483939000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
584757000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
705561000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
933000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18549000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
59913000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36963000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40876000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
81307000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
106505000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
153446000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22622000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20351000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
44565000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
41093000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
63498000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
101658000
us-gaap Operating Expenses
OperatingExpenses
151070000
us-gaap Operating Expenses
OperatingExpenses
194539000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-62565000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-83109000
us-gaap Operating Income Loss
OperatingIncomeLoss
-91157000
us-gaap Operating Income Loss
OperatingIncomeLoss
-157576000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
4381000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
757000
us-gaap Investment Income Interest
InvestmentIncomeInterest
8075000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1175000
CY2023Q2 fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
-393000
CY2022Q2 fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
-5881000
fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
-2111000
fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
-14240000
CY2023Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
5036000
CY2022Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
366000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
9335000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
366000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9810000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7004000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
19521000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15781000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-52755000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-76105000
us-gaap Net Income Loss
NetIncomeLoss
-71636000
us-gaap Net Income Loss
NetIncomeLoss
-141795000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
59000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-531000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1267000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-2619000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-52696000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-76636000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-70369000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-144414000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.47
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.47
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
98400355
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
98400355
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
96704413
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96704413
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
98228476
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
98228476
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
96524968
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96524968
us-gaap Profit Loss
ProfitLoss
-71636000
us-gaap Profit Loss
ProfitLoss
-141795000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8657000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5723000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23880000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39873000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
5235000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1398000
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
7196000
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
763000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-40296000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2793000
fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
-2111000
fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
-14240000
fate Grant Income From Cirm Award
GrantIncomeFromCirmAward
4000000
fate Grant Income From Cirm Award
GrantIncomeFromCirmAward
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-35646000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4450000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-15977000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8136000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-24766000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
586000
fate Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
-665000
fate Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
-287000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-57353000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-117772000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5407000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20213000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
206714000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
196115000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
254628000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
249589000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
42507000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
33261000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
265000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6203000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
265000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6203000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14581000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-78308000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
76560000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
148810000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
61979000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
70502000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
612000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1469000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
62000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
518000
us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.60
CY2023Q2 us-gaap Other Employee Related Liabilities Current And Noncurrent
OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent
12900000
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
10900000
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
2000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s unaudited condensed consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The preparation of the Company’s unaudited condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s unaudited condensed consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company’s unaudited condensed consolidated financial statements relate to its stock price appreciation milestone obligations, contracts containing leases, and accrued expenses. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></p>
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46802000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55275000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
15177000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
15227000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
61979000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
70502000
CY2023Q2 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
15200000
CY2022Q2 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
15200000
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
29100000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
29100000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27700000
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27700000
fate Proceeds From Research And Development Fees Received
ProceedsFromResearchAndDevelopmentFeesReceived
82000000
fate Expected Ressarch Services Period
ExpectedRessarchServicesPeriod
P4Y
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
266608000
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
598000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
270967000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1899000
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023Q2 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2022Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023Q2 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2022Q2 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2023Q2 us-gaap Share Price
SharePrice
4.76
CY2023Q2 us-gaap Share Price
SharePrice
4.76
CY2023Q2 fate Fairvalueassetslevel1 Tolevel2 Transfersamounts
Fairvalueassetslevel1Tolevel2Transfersamounts
0
CY2023Q2 fate Fairvalueassetslevel2 Tolevel1 Transfersamounts
Fairvalueassetslevel2Tolevel1Transfersamounts
0
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
498000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
678000
us-gaap Variable Lease Cost
VariableLeaseCost
1111000
us-gaap Variable Lease Cost
VariableLeaseCost
1295000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
3859000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
4543000
CY2023Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
8396000
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
17899000
CY2023Q2 fate Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
12963000
CY2022Q4 fate Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
16858000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8110000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
19175000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
29469000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53932000
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
These leases have terms varying from one to approximately sixteen years, with renewal options of up to ten years
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P11Y1M6D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0834
CY2023Q2 us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
3361000
CY2022Q2 us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
3865000
us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
6571000
us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
7680000
us-gaap Operating Lease Cost
OperatingLeaseCost
7682000
us-gaap Operating Lease Cost
OperatingLeaseCost
8975000
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
7232000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
14659000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
15087000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
15540000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
16006000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
15057000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
86579000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
170160000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
63812000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
106348000
CY2023Q2 us-gaap Net Rentable Area
NetRentableArea
18913
CY2023Q2 us-gaap Sublease Income
SubleaseIncome
182000
CY2022Q2 us-gaap Sublease Income
SubleaseIncome
0
us-gaap Sublease Income
SubleaseIncome
182000
us-gaap Sublease Income
SubleaseIncome
0
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
222000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10983000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12897000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20542000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23880000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39873000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
483939000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1208000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-18881000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
477472000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
81000
CY2023Q2 fate Conversion Of Preferred Shares To Common Stock Shares
ConversionOfPreferredSharesToCommonStockShares
-33441
fate Conversion Of Preferred Shares To Common Stock Value
ConversionOfPreferredSharesToCommonStockValue
1000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12897000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
59000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-52755000
CY2023Q2 us-gaap Shares Issued
SharesIssued
2761108
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
437755000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
678838000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3001000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19331000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2088000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-65690000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
633393000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3184000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20542000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-531000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-76105000
CY2022Q2 us-gaap Shares Outstanding
SharesOutstanding
96862797
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
580483000

Files In Submission

Name View Source Status
0000950170-23-039803-index-headers.html Edgar Link pending
0000950170-23-039803-index.html Edgar Link pending
0000950170-23-039803.txt Edgar Link pending
0000950170-23-039803-xbrl.zip Edgar Link pending
fate-20230630.htm Edgar Link pending
fate-20230630.xsd Edgar Link pending
fate-ex10_1.htm Edgar Link pending
fate-ex31_1.htm Edgar Link pending
fate-ex31_2.htm Edgar Link pending
fate-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
fate-20230630_def.xml Edgar Link unprocessable
fate-20230630_lab.xml Edgar Link unprocessable
fate-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
fate-20230630_htm.xml Edgar Link completed
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
fate-20230630_cal.xml Edgar Link unprocessable